Analysis of Glucose Levels in Patients Hospitalized With COVID-19 During the First Phase of This Pandemic in West Texas.
Identifieur interne : 000043 ( Main/Exploration ); précédent : 000042; suivant : 000044Analysis of Glucose Levels in Patients Hospitalized With COVID-19 During the First Phase of This Pandemic in West Texas.
Auteurs : Sanjana Rao [États-Unis] ; Kiran Ali [États-Unis] ; Jeff Dennis [États-Unis] ; Gilbert Berdine [États-Unis] ; Victor Test [États-Unis] ; Kenneth Nugent [États-Unis]Source :
- Journal of primary care & community health [ 2150-1327 ]
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Appréciation des risques (MeSH), Femelle (MeSH), Glycémie (analyse), Hospitalisation (statistiques et données numériques), Humains (MeSH), Hyperglycémie (mortalité), Hyperglycémie (épidémiologie), Infections à coronavirus (mortalité), Infections à coronavirus (sang), Infections à coronavirus (thérapie), Infections à coronavirus (épidémiologie), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (mortalité), Pneumopathie virale (sang), Pneumopathie virale (thérapie), Pneumopathie virale (épidémiologie), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Texas (épidémiologie).
- MESH :
- analyse : Glycémie.
- mortalité : Hyperglycémie, Infections à coronavirus, Pneumopathie virale.
- sang : Infections à coronavirus, Pneumopathie virale.
- statistiques et données numériques : Hospitalisation.
- thérapie : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Hyperglycémie, Infections à coronavirus, Pneumopathie virale, Texas.
- Adulte d'âge moyen, Appréciation des risques, Femelle, Humains, Mâle, Pandémies, Résultat thérapeutique, Sujet âgé.
English descriptors
- KwdEn :
- Aged (MeSH), Blood Glucose (analysis), Coronavirus Infections (blood), Coronavirus Infections (epidemiology), Coronavirus Infections (mortality), Coronavirus Infections (therapy), Female (MeSH), Hospitalization (statistics & numerical data), Humans (MeSH), Hyperglycemia (epidemiology), Hyperglycemia (mortality), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (blood), Pneumonia, Viral (epidemiology), Pneumonia, Viral (mortality), Pneumonia, Viral (therapy), Risk Assessment (MeSH), Texas (epidemiology), Treatment Outcome (MeSH).
- MESH :
- chemical , analysis : Blood Glucose.
- geographic , epidemiology : Texas.
- blood : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Hyperglycemia, Pneumonia, Viral.
- mortality : Coronavirus Infections, Hyperglycemia, Pneumonia, Viral.
- statistics & numerical data : Hospitalization.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Aged, Female, Humans, Male, Middle Aged, Pandemics, Risk Assessment, Treatment Outcome.
Abstract
BACKGROUND
Patients with hyperglycemia during hospitalization, especially during ICU hospitalizations, often have worse outcomes, even if they do not have a premorbid diagnosis of diabetes. High glucose levels can provide insight into the underlying pathogenesis of a disease and can contribute to tissue injury. Some patients with COVID-19 have hyperglycemia during hospitalizations.
METHODS
The Infectious Disease and Control office at University Medical Center in Lubbock, Texas, provided a list of patients with a COVID-19 infection hospitalized between March 1 and May 15, 2020. The medical records were reviewed to collect information on age, gender, history of diabetes, and glucose levels on admission and through the first 7 days of hospitalization.
RESULTS
This study included 63 patients with a mean age of 62.1 ± 14.1 years. Thirty-five patients (55.6%) were males. The in-hospital mortality rate was 30.2%. The mean admission glucose level was 129.4 ± 57.1 mg/dL in patients who survived (N = 47) and 189.6 ± 112.2 mg/dL in patients who died during hospitalization (N = 16,
CONCLUSIONS
Patients who died during hospitalization for COVID-19 had higher admission glucose levels than patients who survived. Larger differences between maximum and minimum glucose levels during the first 7 days of hospitalization were associated with increased mortality. These results suggest that high glucose levels identify patients at increased risk for mortality and warrant more study.
DOI: 10.1177/2150132720958533
PubMed: 32924762
PubMed Central: PMC7493238
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Analysis of Glucose Levels in Patients Hospitalized With COVID-19 During the First Phase of This Pandemic in West Texas.</title><author><name sortKey="Rao, Sanjana" sort="Rao, Sanjana" uniqKey="Rao S" first="Sanjana" last="Rao">Sanjana Rao</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Ali, Kiran" sort="Ali, Kiran" uniqKey="Ali K" first="Kiran" last="Ali">Kiran Ali</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Dennis, Jeff" sort="Dennis, Jeff" uniqKey="Dennis J" first="Jeff" last="Dennis">Jeff Dennis</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Berdine, Gilbert" sort="Berdine, Gilbert" uniqKey="Berdine G" first="Gilbert" last="Berdine">Gilbert Berdine</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Test, Victor" sort="Test, Victor" uniqKey="Test V" first="Victor" last="Test">Victor Test</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Nugent, Kenneth" sort="Nugent, Kenneth" uniqKey="Nugent K" first="Kenneth" last="Nugent">Kenneth Nugent</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 Jan-Dec</date><idno type="RBID">pubmed:32924762</idno><idno type="pmid">32924762</idno><idno type="doi">10.1177/2150132720958533</idno><idno type="pmc">PMC7493238</idno><idno type="wicri:Area/Main/Corpus">000229</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000229</idno><idno type="wicri:Area/Main/Curation">000229</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000229</idno><idno type="wicri:Area/Main/Exploration">000229</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Analysis of Glucose Levels in Patients Hospitalized With COVID-19 During the First Phase of This Pandemic in West Texas.</title><author><name sortKey="Rao, Sanjana" sort="Rao, Sanjana" uniqKey="Rao S" first="Sanjana" last="Rao">Sanjana Rao</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Ali, Kiran" sort="Ali, Kiran" uniqKey="Ali K" first="Kiran" last="Ali">Kiran Ali</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Dennis, Jeff" sort="Dennis, Jeff" uniqKey="Dennis J" first="Jeff" last="Dennis">Jeff Dennis</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Berdine, Gilbert" sort="Berdine, Gilbert" uniqKey="Berdine G" first="Gilbert" last="Berdine">Gilbert Berdine</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Test, Victor" sort="Test, Victor" uniqKey="Test V" first="Victor" last="Test">Victor Test</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Nugent, Kenneth" sort="Nugent, Kenneth" uniqKey="Nugent K" first="Kenneth" last="Nugent">Kenneth Nugent</name><affiliation wicri:level="2"><nlm:affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Tech University Health Sciences Center, Lubbock, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><series><title level="j">Journal of primary care & community health</title><idno type="eISSN">2150-1327</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Blood Glucose (analysis)</term><term>Coronavirus Infections (blood)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (mortality)</term><term>Coronavirus Infections (therapy)</term><term>Female (MeSH)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Hyperglycemia (epidemiology)</term><term>Hyperglycemia (mortality)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (blood)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (mortality)</term><term>Pneumonia, Viral (therapy)</term><term>Risk Assessment (MeSH)</term><term>Texas (epidemiology)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Appréciation des risques (MeSH)</term><term>Femelle (MeSH)</term><term>Glycémie (analyse)</term><term>Hospitalisation (statistiques et données numériques)</term><term>Humains (MeSH)</term><term>Hyperglycémie (mortalité)</term><term>Hyperglycémie (épidémiologie)</term><term>Infections à coronavirus (mortalité)</term><term>Infections à coronavirus (sang)</term><term>Infections à coronavirus (thérapie)</term><term>Infections à coronavirus (épidémiologie)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (mortalité)</term><term>Pneumopathie virale (sang)</term><term>Pneumopathie virale (thérapie)</term><term>Pneumopathie virale (épidémiologie)</term><term>Résultat thérapeutique (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Texas (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Blood Glucose</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Texas</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Glycémie</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Hyperglycemia</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term><term>Hyperglycemia</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Hyperglycémie</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Hospitalisation</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Hyperglycémie</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Texas</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Risk Assessment</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Appréciation des risques</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pandémies</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Patients with hyperglycemia during hospitalization, especially during ICU hospitalizations, often have worse outcomes, even if they do not have a premorbid diagnosis of diabetes. High glucose levels can provide insight into the underlying pathogenesis of a disease and can contribute to tissue injury. Some patients with COVID-19 have hyperglycemia during hospitalizations.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>The Infectious Disease and Control office at University Medical Center in Lubbock, Texas, provided a list of patients with a COVID-19 infection hospitalized between March 1 and May 15, 2020. The medical records were reviewed to collect information on age, gender, history of diabetes, and glucose levels on admission and through the first 7 days of hospitalization.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>This study included 63 patients with a mean age of 62.1 ± 14.1 years. Thirty-five patients (55.6%) were males. The in-hospital mortality rate was 30.2%. The mean admission glucose level was 129.4 ± 57.1 mg/dL in patients who survived (N = 47) and 189.6 ± 112.2 mg/dL in patients who died during hospitalization (N = 16, </p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Patients who died during hospitalization for COVID-19 had higher admission glucose levels than patients who survived. Larger differences between maximum and minimum glucose levels during the first 7 days of hospitalization were associated with increased mortality. These results suggest that high glucose levels identify patients at increased risk for mortality and warrant more study.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32924762</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2150-1327</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><MedlineDate>2020 Jan-Dec</MedlineDate></PubDate></JournalIssue><Title>Journal of primary care & community health</Title><ISOAbbreviation>J Prim Care Community Health</ISOAbbreviation></Journal><ArticleTitle>Analysis of Glucose Levels in Patients Hospitalized With COVID-19 During the First Phase of This Pandemic in West Texas.</ArticleTitle><Pagination><MedlinePgn>2150132720958533</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/2150132720958533</ELocationID><Abstract><AbstractText Label="BACKGROUND">Patients with hyperglycemia during hospitalization, especially during ICU hospitalizations, often have worse outcomes, even if they do not have a premorbid diagnosis of diabetes. High glucose levels can provide insight into the underlying pathogenesis of a disease and can contribute to tissue injury. Some patients with COVID-19 have hyperglycemia during hospitalizations.</AbstractText><AbstractText Label="METHODS">The Infectious Disease and Control office at University Medical Center in Lubbock, Texas, provided a list of patients with a COVID-19 infection hospitalized between March 1 and May 15, 2020. The medical records were reviewed to collect information on age, gender, history of diabetes, and glucose levels on admission and through the first 7 days of hospitalization.</AbstractText><AbstractText Label="RESULTS">This study included 63 patients with a mean age of 62.1 ± 14.1 years. Thirty-five patients (55.6%) were males. The in-hospital mortality rate was 30.2%. The mean admission glucose level was 129.4 ± 57.1 mg/dL in patients who survived (N = 47) and 189.6 ± 112.2 mg/dL in patients who died during hospitalization (N = 16, <i>P</i> = .007). An admission glucose greater than 180 mg/dL predicted mortality in a model adjusted for a diabetes, age, and male gender. The mean differences between the maximum and minimum glucose levels calculated over the first 7 days of hospitalization were 112.93 ± 115.4 (N = 47) in patients who survived and were 240.5 ± 97.7 (N = 15) in patients who died during hospitalization (<i>P</i> = .0003). A difference between the maximum and minimum glucose level greater than 105 mg/dL was associated with increased mortality.</AbstractText><AbstractText Label="CONCLUSIONS">Patients who died during hospitalization for COVID-19 had higher admission glucose levels than patients who survived. Larger differences between maximum and minimum glucose levels during the first 7 days of hospitalization were associated with increased mortality. These results suggest that high glucose levels identify patients at increased risk for mortality and warrant more study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Sanjana</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1859-5749</Identifier><AffiliationInfo><Affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Kiran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennis</LastName><ForeName>Jeff</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0264-3635</Identifier><AffiliationInfo><Affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berdine</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Test</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nugent</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2781-4816</Identifier><AffiliationInfo><Affiliation>Texas Tech University Health Sciences Center, Lubbock, TX, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Prim Care Community Health</MedlineTA><NlmUniqueID>101518419</NlmUniqueID><ISSNLinking>2150-1319</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006943" MajorTopicYN="N">Hyperglycemia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013781" MajorTopicYN="N" Type="Geographic">Texas</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">glucose</Keyword><Keyword MajorTopicYN="Y">glucose variability</Keyword><Keyword MajorTopicYN="Y">mortality</Keyword><Keyword MajorTopicYN="Y">outcomes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>14</Day><Hour>15</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32924762</ArticleId><ArticleId IdType="doi">10.1177/2150132720958533</ArticleId><ArticleId IdType="pmc">PMC7493238</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Diabetologia. 2020 Oct;63(10):2102-2111</Citation><ArticleIdList><ArticleId IdType="pubmed">32647915</ArticleId></ArticleIdList></Reference><Reference><Citation>Cureus. 2019 Oct 29;11(10):e6027</Citation><ArticleIdList><ArticleId IdType="pubmed">31824794</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Gastroenterol Hepatol. 2020 Aug;18(9):2128-2130.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">32334082</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Res Clin Pract. 2020 May;163:108186</Citation><ArticleIdList><ArticleId IdType="pubmed">32360400</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Res Clin Pract. 2020 Aug;166:108279</Citation><ArticleIdList><ArticleId IdType="pubmed">32592843</ArticleId></ArticleIdList></Reference><Reference><Citation>J Investig Med. 2020 Mar;68(3):738-742</Citation><ArticleIdList><ArticleId IdType="pubmed">31672720</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2017 Apr;40(4):509-517</Citation><ArticleIdList><ArticleId IdType="pubmed">28325798</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2020 Jul;159(1):367-370</Citation><ArticleIdList><ArticleId IdType="pubmed">32247022</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Sci. 2016 Feb;351(2):201-11</Citation><ArticleIdList><ArticleId IdType="pubmed">26897277</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2016 Jul;44(7):1338-46</Citation><ArticleIdList><ArticleId IdType="pubmed">26958752</ArticleId></ArticleIdList></Reference><Reference><Citation>J Diabetes Sci Technol. 2020 Jul;14(4):813-821</Citation><ArticleIdList><ArticleId IdType="pubmed">32389027</ArticleId></ArticleIdList></Reference><Reference><Citation>J Diabetes Complications. 2014 Sep-Oct;28(5):662-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25044235</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Diabetol. 2010 Sep;47(3):193-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19333547</ArticleId></ArticleIdList></Reference><Reference><Citation>J Community Hosp Intern Med Perspect. 2019 Jun 19;9(3):195-202</Citation><ArticleIdList><ArticleId IdType="pubmed">31258857</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Res Clin Pract. 2020 Jun;164:108185</Citation><ArticleIdList><ArticleId IdType="pubmed">32360710</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Ter Intensiva. 2017 Jul-Sep;29(3):364-372</Citation><ArticleIdList><ArticleId IdType="pubmed">29044305</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2008 May;57(5):1349-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18299315</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Dis. 2016 Jul;8(7):E575-7</Citation><ArticleIdList><ArticleId IdType="pubmed">27500440</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Rao, Sanjana" sort="Rao, Sanjana" uniqKey="Rao S" first="Sanjana" last="Rao">Sanjana Rao</name></region><name sortKey="Ali, Kiran" sort="Ali, Kiran" uniqKey="Ali K" first="Kiran" last="Ali">Kiran Ali</name><name sortKey="Berdine, Gilbert" sort="Berdine, Gilbert" uniqKey="Berdine G" first="Gilbert" last="Berdine">Gilbert Berdine</name><name sortKey="Dennis, Jeff" sort="Dennis, Jeff" uniqKey="Dennis J" first="Jeff" last="Dennis">Jeff Dennis</name><name sortKey="Nugent, Kenneth" sort="Nugent, Kenneth" uniqKey="Nugent K" first="Kenneth" last="Nugent">Kenneth Nugent</name><name sortKey="Test, Victor" sort="Test, Victor" uniqKey="Test V" first="Victor" last="Test">Victor Test</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000043 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000043 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32924762
|texte= Analysis of Glucose Levels in Patients Hospitalized With COVID-19 During the First Phase of This Pandemic in West Texas.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32924762" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |